KDM6B and cardiac hypertrophy: In this study, JMJD3 also aggravated DOX-induced chronic cardiomyopathy and cardiotoxicity, which revealed JMJD3 was a potential target in the therapeutic of cardiomyopathy and cardiac hypertrophy.